RREB1: A Potential Drug Target and Biomarker for Ras-Induced Lung Cancer

Target Name: RREB1

NCBI ID: G6239

RREB1

RREB1: A Potential Drug Target and Biomarker for Ras-Induced Lung Cancer

Introduction

Lung cancer is one of the leading causes of cancer-related deaths worldwide, accounting for over 1.8 million cases and 15% of all cancer deaths in the United States alone. The development of new treatments and biomarkers for this disease remains a major focus in the fight against cancer. One of the promising candidates for cancer treatment is the protein RREB1, which is a key regulator of cell signaling pathways that are often disrupted in lung cancer. In this article, we will explore the biology of RREB1 and its potential as a drug target and biomarker for lung cancer.

The RREB1 gene and its function

The RREB1 gene is located on chromosome 1p36 and encodes a protein named RREB1. RREB1 is a 21-kDa protein that plays a critical role in the regulation of cell signaling pathways, including G/protein-coupled receptor (GPCR) signaling pathways. GPCR signaling is a signaling pathway that is widely present in various cell types, which is involved in the regulation of cellular processes such as cell growth, differentiation, and survival.

RREB1 is a GPCR-associated protein that can interact with multiple GPCRs, including the B-arrestin protein (BAP) and the S/Tau protein. The interaction between RREB1 and BAP is critical for the regulation of BAP-mediated signaling pathways, which are often disrupted in lung cancer. BAP is a negative regulator of the PI3K/Akt signaling pathway, which is involved in the regulation of cell proliferation, survival, and angiogenesis. The deregulation of PI3K/Akt signaling pathways is a common feature of many types of cancer, including lung cancer.

In addition to its role in GPCR signaling, RREB1 is also involved in the regulation of cell adhesion and migration. RREB1 has been shown to play a critical role in the regulation of tight junction formation in epithelial cells, which is involved in the barrier function of the skin and lungs. RREB1 has also been shown to be involved in the regulation of adherens junction formation in epithelial cells, which is involved in cell-cell adhesion and the regulation of cell migration.

RREB1 as a drug target and biomarker

The potential drug targets for RREB1 are numerous and diverse. One of the most promising targets is the inhibition of RREB1 function, which has been shown to be an effective way to inhibit the growth and survival of lung cancer cells. The BAP inhibitor Y27632 is a small molecule that can inhibit the interaction between RREB1 and BAP, thereby inhibiting the regulation of BAP-mediated signaling pathways.

Another potential drug target for RREB1 is the inhibition of its expression. The RNA polymerase II (RNA-II) is a key transcription factor that is involved in the regulation of gene expression in many cell types, including cancer cells. RREB1 is a target of RNA-II, and inhibition of RREB1 expression has been shown to be effective in inhibiting the growth and survival of lung cancer cells.

In addition to its potential as a drug target, RREB1 may also be a useful biomarker for the diagnosis and prognosis of lung cancer. The expression of RREB1 has been shown to be highly correlated with the expression of many cancer-related genes, including the T cell receptor (TCR), which is involved in the regulation of adaptive immunity. Therefore, the expression of RREB1 may be a useful biomarker for the diagnosis and prognosis of

Protein Name: Ras Responsive Element Binding Protein 1

Functions: Transcription factor that binds specifically to the RAS-responsive elements (RRE) of gene promoters (PubMed:9305772, PubMed:15067362, PubMed:8816445, PubMed:10390538, PubMed:17550981). Represses the angiotensinogen gene (PubMed:15067362). Negatively regulates the transcriptional activity of AR (PubMed:17550981). Potentiates the transcriptional activity of NEUROD1 (PubMed:12482979). Promotes brown adipocyte differentiation (By similarity). May be involved in Ras/Raf-mediated cell differentiation by enhancing calcitonin expression (PubMed:8816445)

The "RREB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RREB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets